KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) EBITDA Margin (2016 - 2025)

Resmed (RMD) has disclosed EBITDA Margin for 17 consecutive years, with 34.56% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 201.0% year-over-year to 34.56%, compared with a TTM value of 33.7% through Dec 2025, up 203.0%, and an annual FY2025 reading of 34.92%, up 485.0% over the prior year.
  • EBITDA Margin was 34.56% for Q4 2025 at Resmed, up from 33.43% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 34.56% in Q4 2025 and bottomed at 23.66% in Q4 2023.
  • Average EBITDA Margin over 5 years is 29.36%, with a median of 28.99% recorded in 2021.
  • The sharpest move saw EBITDA Margin crashed -345bps in 2023, then skyrocketed 889bps in 2024.
  • Year by year, EBITDA Margin stood at 27.79% in 2021, then decreased by -2bps to 27.1% in 2022, then fell by -13bps to 23.66% in 2023, then surged by 38bps to 32.54% in 2024, then grew by 6bps to 34.56% in 2025.
  • Business Quant data shows EBITDA Margin for RMD at 34.56% in Q4 2025, 33.43% in Q3 2025, and 33.72% in Q2 2025.